ES2571127T3 - Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos - Google Patents

Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos

Info

Publication number
ES2571127T3
ES2571127T3 ES11788227T ES11788227T ES2571127T3 ES 2571127 T3 ES2571127 T3 ES 2571127T3 ES 11788227 T ES11788227 T ES 11788227T ES 11788227 T ES11788227 T ES 11788227T ES 2571127 T3 ES2571127 T3 ES 2571127T3
Authority
ES
Spain
Prior art keywords
particles
target molecules
separation
samples containing
fibrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11788227T
Other languages
English (en)
Inventor
Amar Rida
Nicolas Mermod
Patrice Francois
Vladimir Lazarevic
Jacques Schrenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm International SA
Original Assignee
Debiopharm International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm International SA filed Critical Debiopharm International SA
Application granted granted Critical
Publication of ES2571127T3 publication Critical patent/ES2571127T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/14—Streptococcus; Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Método para el procesamiento de una muestra líquida que comprende fibrinógeno, para la separación y concentración de moléculas o partículas objetivo de la muestra, que comprende: a. Atrapar dichas moléculas o partículas objetivo en una red de fibrina sometiendo la muestra a trombina o enzimas de tipo trombina para convertir, como mínimo, parcialmente el fibrinógeno contenido en la dicha muestra en fibrina para formar la red de fibrina b. Retraer dicha red de fibrina para formar un coágulo de fibrina c. Separar de dicho coágulo de fibrina del medio de muestra circundante.
ES11788227T 2010-09-15 2011-09-15 Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos Active ES2571127T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH14782010 2010-09-15
CH20412010 2010-12-07
CH12072011 2011-07-20
PCT/IB2011/054035 WO2012035508A2 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components

Publications (1)

Publication Number Publication Date
ES2571127T3 true ES2571127T3 (es) 2016-05-24

Family

ID=45044632

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11788227T Active ES2571127T3 (es) 2010-09-15 2011-09-15 Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos
ES16154770T Active ES2751660T3 (es) 2010-09-15 2011-09-15 Dispositivo que incluye componentes sanguíneos para separar moléculas o partículas diana de muestras

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16154770T Active ES2751660T3 (es) 2010-09-15 2011-09-15 Dispositivo que incluye componentes sanguíneos para separar moléculas o partículas diana de muestras

Country Status (18)

Country Link
US (3) US9689881B2 (es)
EP (2) EP3067431B1 (es)
JP (1) JP5999776B2 (es)
KR (1) KR101948944B1 (es)
CN (2) CN107389932B (es)
AU (2) AU2011303467C1 (es)
CA (1) CA2811493C (es)
CY (1) CY1122166T1 (es)
DK (2) DK3067431T3 (es)
ES (2) ES2571127T3 (es)
HK (1) HK1247280A1 (es)
HR (1) HRP20191785T1 (es)
HU (2) HUE028915T2 (es)
LT (1) LT3067431T (es)
PL (2) PL2616550T3 (es)
PT (1) PT3067431T (es)
SI (1) SI3067431T1 (es)
WO (1) WO2012035508A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067431B1 (en) 2010-09-15 2019-07-24 Debiopharm International S.A. Device including blood components for separating target molecules or particles from samples
ES2811085T7 (es) 2011-06-27 2021-11-29 Univ Emory Composiciones, usos y preparación de lisados de plaquetas
EP2979093B1 (en) * 2013-03-29 2019-10-23 Siemens Healthcare Diagnostics Inc. Rare cell concentration
SI3148698T1 (sl) 2014-06-01 2019-09-30 Debiopharm International Sa Forum "Apres-Demain" Naprava za jemanje in obdelavo vzorcev
AU2017230806B2 (en) 2016-03-10 2021-06-24 Arthrex, Inc. Systems and methods for preparing a thrombin serum
AU2017230810B2 (en) 2016-03-10 2022-03-10 Arthrex, Inc. Systems and methods for preparing protein enhanced serums

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1035260A (en) * 1974-08-12 1978-07-25 Baxter Travenol Laboratories Collection and processing tube
FR2625321B1 (fr) * 1987-12-24 1992-10-02 Pasteur Institut Reactif pour le diagnostic de staphylococcus aureus par agglutination
DE3803463A1 (de) * 1988-02-05 1989-08-17 Linhart Axel Semiquantitativer kalzium-schnelltest
EP0325106B1 (de) * 1988-01-05 1992-10-21 Axel Dr. Linhart Verfahren und Test-Kit zur semiquantitativen Bestimmung des Kalziumgehaltes im Blut
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
ES2113492T3 (es) * 1992-09-09 1998-05-01 Tokuyama Corp Metodo de valoracion de fibrinogeno, reactivo seco para dicha valoracion, y procedimiento para su preparacion.
JP3292760B2 (ja) * 1993-04-22 2002-06-17 テルモ株式会社 採血管およびその製造方法
US5670329A (en) * 1993-05-28 1997-09-23 Cardiovascular Diagnostics, Inc. Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field
AU679822B2 (en) 1993-12-03 1997-07-10 Gordon L. Dorn Method for improving quantitative recovery of microorganisms from specimens containing blood components
DE19602673A1 (de) * 1996-01-25 1997-08-07 Pereg Gmbh Synthetische Testanschmutzung
US6121232A (en) * 1997-01-31 2000-09-19 Omrix Biopharmaceuticals Sa Stabilized mixture comprising fibrinogen
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
JP2000262499A (ja) * 2000-01-01 2000-09-26 Terumo Corp 採血管
US6686204B2 (en) * 2001-08-27 2004-02-03 Becton, Dickinson & Company Collection device
CA2462599A1 (en) * 2001-10-03 2003-04-10 Christopher J. Woolverton Storage-stable fibrinogen solutions
CN100350252C (zh) * 2002-05-01 2007-11-21 瑟纳普斯有限责任公司 实时测定凝血酶活性的方法及实施该方法的试剂盒
DE50207801D1 (de) 2002-09-18 2006-09-21 Sirs Lab Gmbh Verfahren zum Nachweis prokaryontischer DNA
JP4662932B2 (ja) * 2003-08-15 2011-03-30 ユニバーシティー オブ サウス フロリダ 試料からの病原体の捕獲およびアウリントリカルボン酸除去のための物質および方法
US20050065454A1 (en) * 2003-09-22 2005-03-24 Becton, Dickinson And Company Non-evacuated blood collection tube
US7399609B2 (en) * 2003-12-30 2008-07-15 3M Innovative Properties Company Staphylococcus detection
US8419722B2 (en) * 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
DE102005009479A1 (de) 2005-03-02 2006-09-07 Molzym Gmbh & Co. Kg Verwendung von Nukleasen zum Abbau von Nukleinsäure in Gegenwart von chaotropen Agenzien und/oder Tensiden
EP1913144A1 (en) * 2005-07-29 2008-04-23 Ecole Polytechnique Fédérale de Lausanne Molecular variant fibrinogen fusion proteins
KR20100017576A (ko) * 2007-05-03 2010-02-16 아큐메트릭스, 인크. 트롬빈 수용체 길항제에 의한 혈소판 응집 억제의 측정 방법
JP2010535016A (ja) 2007-08-02 2010-11-18 ユニヴェルシテ・ラヴァル 体液から微生物細胞および微生物核酸の濃縮および富化
JP5029217B2 (ja) * 2007-08-27 2012-09-19 東レ株式会社 シート状物の製造方法
BRPI0915574A2 (pt) * 2008-07-09 2016-07-26 Profibrix Bv sequência nucleotídica, construção nucleotídica, célula ou linhagem celular, método para produção de fibrinogênio em um sistema de cultura de célula eucariótica, preparação de fibrinogênio, uso da preparação de fibrinogênio, método para seleção de célula ou linhagem celular
US9353160B2 (en) 2009-07-16 2016-05-31 Glaxosmithkline Biologicals S.A. Method of prophlactically treating infection using a recombinant fibrinogen binding protein clumping factor A (ClfA) or fragment thereof
EP3067431B1 (en) 2010-09-15 2019-07-24 Debiopharm International S.A. Device including blood components for separating target molecules or particles from samples

Also Published As

Publication number Publication date
WO2012035508A3 (en) 2012-05-18
CY1122166T1 (el) 2020-11-25
CA2811493A1 (en) 2012-03-22
LT3067431T (lt) 2019-11-11
JP2013538355A (ja) 2013-10-10
PL2616550T3 (pl) 2016-08-31
US20210148940A1 (en) 2021-05-20
EP2616550B1 (en) 2016-02-10
AU2011303467B2 (en) 2016-09-15
WO2012035508A2 (en) 2012-03-22
EP3067431B1 (en) 2019-07-24
HK1247280A1 (zh) 2018-09-21
ES2751660T3 (es) 2020-04-01
AU2011303467C1 (en) 2017-03-09
CN103108959A (zh) 2013-05-15
JP5999776B2 (ja) 2016-09-28
EP3067431A1 (en) 2016-09-14
PT3067431T (pt) 2019-10-29
US20130164737A1 (en) 2013-06-27
CN107389932B (zh) 2019-11-22
HUE028915T2 (en) 2017-01-30
EP2616550A2 (en) 2013-07-24
AU2016266066A1 (en) 2016-12-22
US9689881B2 (en) 2017-06-27
CN103108959B (zh) 2017-06-09
CN107389932A (zh) 2017-11-24
KR20130107300A (ko) 2013-10-01
CA2811493C (en) 2020-06-16
SI3067431T1 (sl) 2019-11-29
HUE045771T2 (hu) 2020-01-28
AU2011303467A1 (en) 2013-04-04
US20170336424A1 (en) 2017-11-23
DK3067431T3 (da) 2019-10-14
AU2016266066B2 (en) 2017-12-21
KR101948944B1 (ko) 2019-02-15
HRP20191785T1 (hr) 2019-12-27
DK2616550T3 (en) 2016-05-23
PL3067431T3 (pl) 2019-12-31
WO2012035508A4 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
ES2571127T3 (es) Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos
WO2014028378A3 (en) Methods and systems for detecting biological components
BR112013025758A2 (pt) monitoramento de misturas de amplificação de recombinase polimerase
WO2013126774A3 (en) Microfluidic devices for capture of target species
WO2012103479A3 (en) Gas sorption analysis of unconventional rock samples
CR20120326A (es) Dispositivo portátil de monitorización de la coagulación y método de evaluación de la respuesta de coagulación
EA201491833A1 (ru) Основанные на клетках перекрестные анализы и их применение
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
BR112012024206A2 (pt) método e sistema para analisar uma amostra de sangue
WO2011088014A3 (en) Systems and methods for counting cells and biomolecules
WO2012139047A3 (en) Identifying and enumerating early granulated cells (egcs)
WO2012122564A3 (en) Diagnostic and sample preparation devices and methods
MX2013003116A (es) Preparacion de suero.
EA201892663A1 (ru) Аналоги фосфолипидного эфира для идентификации и выделения циркулирующих опухолевых клеток
WO2010011358A3 (en) Method and medium for detecting the presence or absence of staphylococcus aureus in a test sample
WO2012040603A3 (en) Use of diazolidinyl urea for anti-clumping of biological samples
MX358997B (es) Metodo para evaluar la reaccion de coagulacion sanguinea.
IN2015DN01608A (es)
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
CO6990738A2 (es) Agentes de reversion anticoagulante
EA201500377A1 (ru) Способ обнаружения анализируемого вещества и определение его концентрации с использованием намагничиваемых гранул
PH12014501445A1 (en) Detection of human umbilical cord tissue-derived cells
CO6430443A2 (es) Analisis multiplex de proteina transgenica apilada.
WO2011132978A3 (ko) 듀얼 광원을 포함하는 형광 편광 분석 장치
GR1007341B (el) Διαγνωστικος προσδιορισμος